Clearside Biomedical Inc (CLSD)

$1.17

+0.04

(+3.54%)▲

Market is closed - opens 7 PM, 29 Jul 2024

Performance

  • $1.12
    $1.18
    $1.17
    downward going graph

    4.27%

    Downside

    Day's Volatility :4.68%

    Upside

    0.43%

    downward going graph
  • $0.65
    $2.12
    $1.17
    downward going graph

    44.44%

    Downside

    52 Weeks Volatility :69.33%

    Upside

    44.81%

    downward going graph

Returns

PeriodClearside Biomedical IncSector (Health Care)Index (Russel 2000)
3 Months
-15.67%
6.5%
0.0%
6 Months
-8.13%
7.1%
0.0%
1 Year
-8.13%
9.8%
0.0%
3 Years
-77.4%
14.2%
-20.2%

Highlights

Market Capitalization
85.2M
Book Value
- $0.29
Earnings Per Share (EPS)
-0.55
PEG Ratio
0.0
Wall Street Target Price
5.5
Profit Margin
0.0%
Operating Margin TTM
-3569.13%
Return On Assets TTM
-37.5%
Return On Equity TTM
-1310.02%
Revenue TTM
8.5M
Revenue Per Share TTM
0.13
Quarterly Revenue Growth YOY
5650.0%
Gross Profit TTM
1.1M
EBITDA
-25.4M
Diluted Eps TTM
-0.55
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.58
EPS Estimate Next Year
-0.63
EPS Estimate Current Quarter
-0.14
EPS Estimate Next Quarter
-0.14

Analyst Recommendation

Buy
    91%Buy
    8%Hold
    0
    0%Sell
Based on 12 Wall street analysts offering stock ratings for Clearside Biomedical Inc(by analysts ranked 0 to 5 stars)
Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
11
11
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 370.09%

Current $1.17
Target $5.50

Company Financials

FY18Y/Y Change
Revenue
30.0K
↓ 91.3%
Net Income
-82.8M
↑ 40.43%
Net Profit Margin
-276.1K%
↓ 258965.8%
FY19Y/Y Change
Revenue
2.2M
↑ 7143.33%
Net Income
-30.6M
↓ 63.1%
Net Profit Margin
-1.4K%
↑ 274653.7%
FY20Y/Y Change
Revenue
7.9M
↑ 263.28%
Net Income
-18.0M
↓ 41.0%
Net Profit Margin
-228.4%
↑ 1177.9%
FY21Y/Y Change
Revenue
29.6M
↑ 274.65%
Net Income
376.0K
↓ 102.09%
Net Profit Margin
1.27%
↑ 229.67%
FY22Y/Y Change
Revenue
1.3M
↓ 95.51%
Net Income
-34.1M
↓ 9161.53%
Net Profit Margin
-2.6K%
↓ 2568.82%
FY23Y/Y Change
Revenue
8.2M
↑ 519.89%
Net Income
-32.5M
↓ 4.66%
Net Profit Margin
-394.91%
↑ 2172.64%
Q4 FY22Q/Q Change
Revenue
330.0K
↑ 24.06%
Net Income
-8.6M
↓ 3.82%
Net Profit Margin
-2.6K%
↑ 754.51%
Q1 FY23Q/Q Change
Revenue
4.0K
↓ 98.79%
Net Income
-13.1M
↑ 52.78%
Net Profit Margin
-328.1K%
↓ 325447.37%
Q2 FY23Q/Q Change
Revenue
1.0M
↑ 25350.0%
Net Income
-9.1M
↓ 30.61%
Net Profit Margin
-894.5%
↑ 327155.5%
Q3 FY23Q/Q Change
Revenue
859.0K
↓ 15.62%
Net Income
-9.3M
↑ 1.77%
Net Profit Margin
-1.1K%
↓ 184.31%
Q4 FY23Q/Q Change
Revenue
6.3M
↑ 638.65%
Net Income
-4.8M
↓ 47.86%
Net Profit Margin
-76.15%
↑ 1002.66%
Q1 FY24Q/Q Change
Revenue
230.0K
↓ 96.38%
Net Income
-11.8M
↑ 143.44%
Net Profit Margin
-5.1K%
↓ 5038.2%
FY18Y/Y Change
Total Assets
44.1M
↑ 8.96%
Total Liabilities
20.5M
↑ 7.45%
FY19Y/Y Change
Total Assets
26.8M
↓ 39.31%
Total Liabilities
15.6M
↓ 23.81%
FY20Y/Y Change
Total Assets
19.3M
↓ 27.84%
Total Liabilities
10.6M
↓ 32.4%
FY21Y/Y Change
Total Assets
42.9M
↑ 122.04%
Total Liabilities
4.9M
↓ 53.33%
FY22Y/Y Change
Total Assets
51.3M
↑ 19.58%
Total Liabilities
40.7M
↑ 725.81%
FY23Y/Y Change
Total Assets
34.0M
↓ 33.69%
Total Liabilities
49.9M
↑ 22.69%
Q4 FY22Q/Q Change
Total Assets
51.3M
↓ 7.87%
Total Liabilities
40.7M
↑ 9.58%
Q1 FY23Q/Q Change
Total Assets
44.7M
↓ 12.88%
Total Liabilities
42.0M
↑ 3.19%
Q2 FY23Q/Q Change
Total Assets
39.2M
↓ 12.33%
Total Liabilities
44.2M
↑ 5.15%
Q3 FY23Q/Q Change
Total Assets
34.4M
↓ 12.16%
Total Liabilities
47.3M
↑ 7.05%
Q4 FY23Q/Q Change
Total Assets
34.0M
↓ 1.17%
Total Liabilities
49.9M
↑ 5.63%
Q1 FY24Q/Q Change
Total Assets
40.1M
↑ 18.0%
Total Liabilities
62.0M
↑ 24.08%
FY18Y/Y Change
Operating Cash Flow
-79.2M
↑ 55.04%
Investing Cash Flow
-3.8M
↓ 118.69%
Financing Cash Flow
81.8M
↑ 1425.16%
FY19Y/Y Change
Operating Cash Flow
-27.1M
↓ 65.82%
Investing Cash Flow
32.9M
↓ 975.66%
Financing Cash Flow
8.7M
↓ 89.37%
FY20Y/Y Change
Operating Cash Flow
-13.1M
↓ 51.53%
Investing Cash Flow
-55.0K
↓ 100.17%
Financing Cash Flow
7.9M
↓ 9.52%
FY21Y/Y Change
Operating Cash Flow
-10.7M
↓ 18.19%
Investing Cash Flow
-246.0K
↑ 347.27%
Financing Cash Flow
23.8M
↑ 202.3%
FY22Y/Y Change
Operating Cash Flow
-13.4M
↑ 24.52%
Investing Cash Flow
-246.0K
↑ 0.0%
Financing Cash Flow
31.3M
↑ 31.75%
Q4 FY22Q/Q Change
Operating Cash Flow
-5.6M
↓ 9.36%
Investing Cash Flow
-91.0K
↓ 41.29%
Financing Cash Flow
575.0K
↓ 98.13%
Q1 FY23Q/Q Change
Operating Cash Flow
-7.2M
↑ 28.7%
Investing Cash Flow
-115.0K
↑ 26.37%
Financing Cash Flow
332.0K
↓ 42.26%
Q2 FY23Q/Q Change
Operating Cash Flow
-5.3M
↓ 26.01%
Investing Cash Flow
-1.1M
↑ 853.91%
Financing Cash Flow
22.0K
↓ 93.37%

Technicals Summary

Sell

Neutral

Buy

Clearside Biomedical Inc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Clearside Biomedical Inc
Clearside Biomedical Inc
-6.61%
-8.13%
-8.13%
-77.4%
-79.49%
Moderna, Inc.
Moderna, Inc.
-1.67%
18.26%
-0.21%
-64.15%
752.69%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-0.46%
13.21%
45.59%
84.19%
244.2%
Novo Nordisk A/s
Novo Nordisk A/s
-11.0%
18.31%
61.56%
186.46%
423.59%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.85%
14.43%
39.88%
147.45%
195.07%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Clearside Biomedical Inc
Clearside Biomedical Inc
133.0
NA
0.0
-0.58
-13.1
-0.37
NA
-0.29
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.19
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.35
31.35
1.46
44.44
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
44.28
44.28
2.36
3.43
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.85
31.85
0.53
16.98
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Clearside Biomedical Inc
Clearside Biomedical Inc
Buy
$85.2M
-79.49%
133.0
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$45.3B
752.69%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$116.9B
244.2%
31.35
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$572.0B
423.59%
44.28
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.7B
195.07%
31.85
39.46%

Insights on Clearside Biomedical Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 6.34M → 230.0K (in $), with an average decrease of 96.4% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -4.83M → -11.76M (in $), with an average decrease of 143.4% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 69.7%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 263.9%

Institutional Holdings

  • Armistice Capital, LLC

    5.29%

  • Rosalind Advisors, Inc.

    3.47%

  • Vanguard Group Inc

    3.33%

  • Carmignac Gestion

    2.85%

  • BlackRock Inc

    1.01%

  • Geode Capital Management, LLC

    0.86%

Company Information

clearside biomedical, inc. is a pharmaceuticals company located in 1220 old alpharetta rd., suite 300, alpharetta, ga, united states.

Organization
Clearside Biomedical Inc
Employees
30
CEO
Dr. George M. Lasezkay J.D., Pharm.D., Pharma.D.
Industry
Health Technology

Discover More

FAQs